Literature DB >> 17965227

Age and origin of major Smith-Lemli-Opitz syndrome (SLOS) mutations in European populations.

M Witsch-Baumgartner1, I Schwentner, M Gruber, P Benlian, J Bertranpetit, E Bieth, F Chevy, N Clusellas, X Estivill, G Gasparini, M Giros, R I Kelley, M Krajewska-Walasek, J Menzel, T Miettinen, M Ogorelkova, M Rossi, I Scala, A Schinzel, K Schmidt, D Schönitzer, E Seemanova, K Sperling, M Syrrou, P J Talmud, B Wollnik, M Krawczak, D Labuda, G Utermann.   

Abstract

BACKGROUND: Smith-Lemli-Opitz syndrome (SLOS) (MIM 270 400) is an autosomal recessive multiple congenital anomalies/mental retardation syndrome caused by mutations in the Delta7-sterol reductase (DHCR7, E.C.1.3.1.21) gene. The prevalence of SLOS has been estimated to range between 1:15000 and 1:60000 in populations of European origin. METHODS AND
RESULTS: We have analysed the frequency, origin, and age of DHCR7 mutations in European populations. In 263 SLOS patients 10 common alleles (c.964-1G>C, p.Trp151X, p.Thr93Met, p.Val326Leu, p.Arg352Trp, p.Arg404Cys, p.Phe302Leu, p.Leu157Pro, p.Gly410Ser, p.Arg445Gln) were found to constitute approximately 80% of disease-causing mutations. As reported before, the mutational spectra differed significantly between populations, and frequency peaks of common mutations were observed in North-West (c.964-1G>C), North-East (p.Trp151X, p.Val326Leu) and Southern Europe (p.Thr93Met). SLOS was virtually absent from Finland. The analysis of nearly 8000 alleles from 10 different European populations confirmed a geographical distribution of DHCR7 mutations as reported in previous studies. The common Null mutations in Northern Europe (combined ca. 1:70) occurred at a much higher frequency than expected from the reported prevalence of SLOS. In contrast the most common mutation in Mediterranean SLOS patients (p.Thr93Met) had a low population frequency. Haplotypes were constructed for SLOS chromosomes, and for wild-type chromosomes of African and European origins using eight cSNPs in the DHCR7 gene. The DHCR7 orthologue was sequenced in eight chimpanzees (Pan troglodytes) and three microsatellites were analysed in 50 of the SLOS families in order to estimate the age of the three major SLOS-causing mutations.
CONCLUSIONS: The results indicate a time of first appearance of c.964-1G>C and p.Trp151X some 3000 years ago in North-West and North-East Europe, respectively. The p.Thr93Met mutations on the J haplotype has probably first arisen approximately 6000 years ago in the Eastern Mediterranean. Together, it appears that a combination of founder effects, recurrent mutations, and drift have shaped the present frequency distribution of DHCR7 mutations in Europe.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17965227     DOI: 10.1136/jmg.2007.053520

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  21 in total

Review 1.  Malformation syndromes caused by disorders of cholesterol synthesis.

Authors:  Forbes D Porter; Gail E Herman
Journal:  J Lipid Res       Date:  2010-10-07       Impact factor: 5.922

Review 2.  Identifying modifier genes of monogenic disease: strategies and difficulties.

Authors:  Emmanuelle Génin; Josué Feingold; Françoise Clerget-Darpoux
Journal:  Hum Genet       Date:  2008-09-11       Impact factor: 4.132

3.  Birthday of a syndrome: 50 years anniversary of Smith-Lemli-Opitz Syndrome.

Authors:  Martina Witsch-Baumgartner; Barbara Lanthaler
Journal:  Eur J Hum Genet       Date:  2014-05-14       Impact factor: 4.246

4.  Mutational spectrum of smith-lemli-opitz syndrome patients in hungary.

Authors:  I Balogh; K Koczok; G P Szabó; O Török; K Hadzsiev; G Csábi; L Balogh; E Dzsudzsák; E Ajzner; L Szabó; V Csákváry; A V Oláh
Journal:  Mol Syndromol       Date:  2012-11-09

5.  Differences between predicted and established diagnoses of Smith-Lemli-Opitz syndrome in the Polish population: underdiagnosis or loss of affected fetuses?

Authors:  Aleksandra Jezela-Stanek; Elżbieta Ciara; Ewa Małunowicz; Krystyna Chrzanowska; Anna Latos-Bieleńska; Małgorzata Krajewska-Walasek
Journal:  J Inherit Metab Dis       Date:  2010-06-16       Impact factor: 4.982

6.  Sterols and oxysterols in plasma from Smith-Lemli-Opitz syndrome patients.

Authors:  William J Griffiths; Jonas Abdel-Khalik; Peter J Crick; Michael Ogundare; Cedric H Shackleton; Karin Tuschl; Mei Kwun Kwok; Brian W Bigger; Andrew A Morris; Akira Honda; Libin Xu; Ned A Porter; Ingemar Björkhem; Peter T Clayton; Yuqin Wang
Journal:  J Steroid Biochem Mol Biol       Date:  2016-03-11       Impact factor: 4.292

7.  Inhibitors of 7-Dehydrocholesterol Reductase: Screening of a Collection of Pharmacologically Active Compounds in Neuro2a Cells.

Authors:  Hye-Young H Kim; Zeljka Korade; Keri A Tallman; Wei Liu; C David Weaver; Karoly Mirnics; Ned A Porter
Journal:  Chem Res Toxicol       Date:  2016-04-28       Impact factor: 3.739

8.  Maternal ABCA1 genotype is associated with severity of Smith-Lemli-Opitz syndrome and with viability of patients homozygous for null mutations.

Authors:  Barbara Lanthaler; Elisabeth Steichen-Gersdorf; Barbara Kollerits; Johannes Zschocke; Martina Witsch-Baumgartner
Journal:  Eur J Hum Genet       Date:  2012-08-29       Impact factor: 4.246

9.  Identification and characterization of prescription drugs that change levels of 7-dehydrocholesterol and desmosterol.

Authors:  Phillip A Wages; Hye-Young H Kim; Zeljka Korade; Ned A Porter
Journal:  J Lipid Res       Date:  2018-08-07       Impact factor: 5.922

10.  Cholesterol-mediated Degradation of 7-Dehydrocholesterol Reductase Switches the Balance from Cholesterol to Vitamin D Synthesis.

Authors:  Anika V Prabhu; Winnie Luu; Laura J Sharpe; Andrew J Brown
Journal:  J Biol Chem       Date:  2016-02-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.